-

IPA to Present at Jefferies Healthcare Conference 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. The replay of the webcast will be available for 90 days.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.

Contacts

Investor: investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$XBI
Hashtags
#AI
#BioStrand
#Omics
#antibodydiscovery
#bioinformatics
#biotechnology
#biotherapeutics
#covid19
#drugdiscovery
#futurepandemic
#omics
#personalizedmedicine
#polytope
#precisionmedicine
#variants

Contacts

Investor: investors@ipatherapeutics.com

Social Media Profiles
Facebook
Linkedin
Substack
Twitter
YouTube
More News From ImmunoPrecise Antibodies

MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026. The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 of t...

MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced the filing of European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference. The application is intended to protect the enriched biological representation architecture that underpins MindWalk's HYFT® Technology, its ReefIQ™ biological context layer, and its LensAI™ reasoning workflows. The fi...

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr....
Back to Newsroom